Venetoclax Add-On Improves Complete Remission in AML

A phase 2 study found 91% complete remission in patients with AML who received venetoclax plus standard therapy. The study was published as a preprint and has not yet been peer reviewed.
First Look

source https://www.medscape.com/viewarticle/968484?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors